TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05305547
Drug: S-217622
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a round tablet.
Study: NCT05732961
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
Study: NCT06446154
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.
Study: NCT05169060
Drug: Fish Oil Concentrate, 1000 Mg Oral Capsule
Normalized name: Fish Oil Concentrate, 1000 mg oral capsule
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules, 2 grams or 4 grams per day.
Study: NCT06136650
Drug: Opevesostat
Normalized name: Opevesostat
DrugBank: Opevesostat (DB18818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06136650
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06136650
Drug: Fludrocortisone acetate
Normalized name: Fludrocortisone Acetate
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06136650
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally
Study: NCT06136650
Drug: Prednisone acetate
Normalized name: Prednisone acetate
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06136650
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04783857
Drug: Progesterone 200 MG Oral Capsule
Normalized name: Progesterone 200 mg oral capsule
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone, 200mg, once daily, oral tablet/capsule
Study: NCT05123703
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.
Study: NCT05123703
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).
Study: NCT05348577
Drug: capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
Study: NCT05348577
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
Study: NCT05744375
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met.
Study: NCT04884139
Drug: Dolutegravir/Lamivudine as a single pill
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: - Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
Study: NCT04884139
Drug: Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~* Route of adminstration: oral~* Schedule of administration: once a day for 96 weeks.
Study: NCT05797246
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
Study: NCT06137768
Drug: HRS-5965
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5965
Study: NCT05071430
Drug: HB-01
Normalized name: scopolamine hydrobromide 0.01 MG
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Study: NCT06008288
Drug: JAB-21822
Normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
Study: NCT05237687
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be randomly assigned to sirolimus or standard of care
Study: NCT06084936
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
Study: NCT06084936
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
Study: NCT06084936
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
Study: NCT06084936
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
Study: NCT06084936
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
Study: NCT06084936
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
Study: NCT02492074
Drug: Delta-9-tetrahydrocannabinol
Normalized name: Delta-9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of delta-9-tetrahydrocannabinol
Study: NCT02492074
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration of cannabidiol
Study: NCT04721548
Drug: Minoxidil Topical Foam
Normalized name: minoxidil Topical Foam
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply 1 mL of solution twice a day.
Study: NCT06463028
Drug: Sapanisertib
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06463028
Drug: Serabelisib
Normalized name: Serabelisib
DrugBank: Serabelisib (DB14935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06463028
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT06035744
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized IgG4 anti-PD-1 monoclonal antibody
Study: NCT04871594
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On day 1, 22, and 43 240mg
Study: NCT04810611
Drug: MBG453
Normalized name: Anti-tim-3 monoclonal antibody mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TIM3 monoclonal antibody
Study: NCT04810611
Drug: NIS793
Normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TGF-β monoclonal antibody
Study: NCT04810611
Drug: canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-1β monoclonal antibody
Study: NCT04240626
Drug: Neurontin
Normalized name: Neurontin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours
Study: NCT04240626
Drug: Oxycodone Hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control
Study: NCT04240626
Drug: Zofran Injection
Normalized name: Zofran Injectable Product
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg IV for nausea control while inpatient, prn
Study: NCT04240626
Drug: Scopolamine patch
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application patch for nausea control, used with/without Ativan.
Study: NCT04240626
Drug: Ativan
Normalized name: Ativan
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control
Study: NCT04240626
Drug: Tylenol Suspension
Normalized name: Tylenol Suspension
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg q6h PRN for pain control.
Study: NCT05885737
Drug: Difelikefalin Injection
Normalized name: difelikefalin Injection
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study: NCT03816319
Drug: UAE Inhibitor TAK-243
Normalized name: Fibrinolysis inhibitor
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05608291
Drug: Fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
Study: NCT05608291
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab will be administered by IV infusion Q 3 weeks
Study: NCT05608291
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered by IV infusion Q 3 weeks
Study: NCT04693351
Drug: Troriluzole
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
Study: NCT05859750
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104 (6mg/kg) on day 1, IV, Q2W
Study: NCT05859750
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104 (10mg/kg) on day 1, IV, Q2W
Study: NCT05859750
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
Study: NCT05859750
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
Study: NCT06354387
Drug: Alectinib (Alecensa), Nivolumab (Opdivo)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
Study: NCT01297400
Drug: Silvadene® Cream 1% [Silver Sulfadiazine]
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application, twice a day
Study: NCT05757219
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
Study: NCT05529992
Drug: Velaglucerase Alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: VPRIV intravenous infusion every other week for 60 minutes.
Study: NCT06477419
Drug: Sacituzumab govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After enrollment, participants will receive SG until disease progression or intolerable toxicity.
Study: NCT05735366
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab as an IV infusion
Study: NCT06356688
Drug: Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel Polymeric Micelles for Injection:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 10mg/kg, IV drip, d3, q3w;
Study: NCT06161571
Drug: Efruxifermin
Normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous (SC) injection
Study: NCT06127810
Drug: Gadopiclenol
Normalized name: Gadopiclenol
DrugBank: Gadopiclenol (DB17084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Gadopiclenol instead of standard of care contrast
Study: NCT06344156
Drug: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
Study: NCT05194072
Drug: SGN-B7H4V
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given into the vein (IV; intravenously)
Study: NCT05194072
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg every 6 weeks, given by IV
Study: NCT05453695
Drug: Intravenous DNase I
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalating intravenous infusion of DNase I
Study: NCT05630976
Drug: Isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single arm study, all enrolled participants will receive the study intervention.
Study: NCT05429632
Drug: mocravimod
Normalized name: Mocravimod
DrugBank: Mocravimod (DB18151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1PR modulator
Study: NCT05650736
Drug: Abrocitinib 200 mg
Normalized name: abrocitinib 200 MG
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
Study: NCT05501288
Drug: compound pholcodine oral solution
Normalized name: pholcodine Oral Solution
DrugBank: Pholcodine (DB09209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
Study: NCT06168812
Drug: Glipizide
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
Study: NCT05042973
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
Study: NCT06519097
Drug: Vitamin E Delta Tocotrienol
Normalized name: tocotrienols / vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily
Study: NCT06529419
Drug: AZD8630
Normalized name: AZD8630
DrugBank: AZD8630 (DB19397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administered by inhalation
Study: NCT05611931
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Study: NCT05522569
Drug: Allogeneic human mesenchymal stem cells (Allo-hMSCs)
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
Study: NCT06233565
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
Study: NCT06233565
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
Study: NCT06233565
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
Study: NCT04833114
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
Study: NCT04833114
Drug: Mabthera
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
Study: NCT04833114
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
Study: NCT04833114
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
Study: NCT04833114
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
Study: NCT06280196
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 on Day 1 of each 21-day cycle of the study
Study: NCT06280196
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
Study: NCT05747534
Drug: Larazotide Acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
Study: NCT06364904
Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W.